Presilium Private Wealth LLC Acquires Shares of 435 Eli Lilly and Company $LLY

Key Points

• Presilium Private Wealth LLC acquired 435 shares of Eli Lilly and Company, valued at approximately $339,000, in the second quarter, contributing to the overall institutional ownership of the company at 82.53%.
• Eli Lilly reported a quarterly earnings per share of $6.31, surpassing analyst estimates, with revenue reaching $15.56 billion, a notable 37.6% increase year-over-year.
• Analysts maintain a consensus rating of "Moderate Buy" for Eli Lilly, with a target price of $948.06 based on recent ratings, indicating a generally positive outlook for its stock.

Presilium Private Wealth LLC acquired a new stake in Eli Lilly and Company (NYSE:LLY - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 435 shares of the company's stock, valued at approximately $339,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Precedent Wealth Partners LLC increased its holdings in Eli Lilly and Company by 15.3% in the second quarter. Precedent Wealth Partners LLC now owns 294 shares of the company's stock valued at $229,000 after buying an additional 39 shares in the last quarter. Capital Advisors Inc. OK increased its stake in shares of Eli Lilly and Company by 6.8% during the second quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company's stock worth $5,260,000 after purchasing an additional 429 shares in the last quarter. Family CFO Inc purchased a new stake in shares of Eli Lilly and Company during the second quarter worth about $54,000. Duquesne Family Office LLC increased its stake in shares of Eli Lilly and Company by 52.5% during the first quarter. Duquesne Family Office LLC now owns 94,830 shares of the company's stock worth $78,321,000 after purchasing an additional 32,640 shares in the last quarter. Finally, Corient IA LLC purchased a new stake in shares of Eli Lilly and Company during the first quarter worth about $570,000. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Performance

LLY opened at $833.08 on Monday. The firm has a market capitalization of $788.47 billion, a PE ratio of 54.45, a PEG ratio of 1.18 and a beta of 0.47. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $937.00. The firm's 50-day moving average price is $742.42 and its 200 day moving average price is $765.55. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. Eli Lilly and Company's quarterly revenue was up 37.6% on a year-over-year basis. During the same period in the previous year, the business posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, sell-side analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the stock. Weiss Ratings reissued a "hold (c+)" rating on shares of Eli Lilly and Company in a research note on Wednesday, October 8th. Daiwa America cut shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Sunday, August 17th. Wall Street Zen cut shares of Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research note on Saturday, September 20th. Hsbc Global Res raised shares of Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research note on Wednesday, August 27th. Finally, HSBC boosted their target price on shares of Eli Lilly and Company from $700.00 to $800.00 in a research note on Wednesday, October 1st. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $948.06.

Insider Buying and Selling

In other news, Director Gabrielle Sulzberger bought 117 shares of the firm's stock in a transaction on Tuesday, August 12th. The shares were bought at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the acquisition, the director directly owned 2,703 shares of the company's stock, valued at $1,733,109.54. This trade represents a 4.52% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director J Erik Fyrwald bought 1,565 shares of the firm's stock in a transaction on Tuesday, August 12th. The stock was purchased at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the acquisition, the director directly owned 74,578 shares in the company, valued at $47,903,686.74. The trade was a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired a total of 4,514 shares of company stock worth $2,894,841 over the last ninety days. 0.14% of the stock is currently owned by insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.